Spectral Platforms
Spectral Platforms is pioneering rapid diagnostic solutions in clinical microbiology, focusing on eliminating time-consuming steps in traditional microbiology to enable faster, more accurate detection and characterization of pathogens. Their proprietary technology leverages sensitive detection of bacterial metabolites and redox state changes, providing results in minutes rather than days. The company aims to improve patient outcomes, particularly in sepsis and infectious disease management, by delivering rapid, reliable, and actionable diagnostic information. Spectral Platforms also offers advanced microbiology services and collaborates with leading institutions and regulatory bodies to validate and deploy their innovations.
Industries
Nr. of Employees
small (1-50)
Spectral Platforms
1851 Huntington Drive, Duarte CA 91010
Patents
Albumin-based non-covalent complexes and methods of use thereof
2025-07-15 • US-12357679-B2
View DetailsSpectroscopic methods to detect and characterize microorganisms
2021-08-31 • US-11105747-B2
View DetailsAlbumin-based non-covalent complexes and methods of use thereof
2019-07-09 • US-10342855-B2
View DetailsAlbumin-based non-covalent complexes and methods of use thereof
2018-09-11 • US-10071141-B2
View Details
Albumin-based non-covalent complexes and methods of use thereof
2025-07-15 • US-12357679-B2
View DetailsSpectroscopic methods to detect and characterize microorganisms
2021-08-31 • US-11105747-B2
View DetailsAlbumin-based non-covalent complexes and methods of use thereof
2019-07-09 • US-10342855-B2
View DetailsAlbumin-based non-covalent complexes and methods of use thereof
2018-09-11 • US-10071141-B2
View DetailsProducts
Rapid blood pathogen presence test (30-minute)
A diagnostic test intended to detect presence of pathogenic microorganisms in blood with results within ~30 minutes for triage of patients at risk of sepsis.
Bacterial identification and direct AST (6–8 hour turnaround)
Workflow to subclassify bacteria in clinical samples and deliver antimicrobial susceptibility results reportedly equivalent to CLSI standards, including for polymicrobial samples (reported: ~8 hours blood, ~6 hours urine).
Differential chromogenic media assay for Candida species (96-well)
96‑well plate format differential media for visual colorimetric discrimination of Candida species (including Candida auris) after incubation (36–54 hours), with optional automated plate reader readout.
Rapid blood pathogen presence test (30-minute)
A diagnostic test intended to detect presence of pathogenic microorganisms in blood with results within ~30 minutes for triage of patients at risk of sepsis.
Bacterial identification and direct AST (6–8 hour turnaround)
Workflow to subclassify bacteria in clinical samples and deliver antimicrobial susceptibility results reportedly equivalent to CLSI standards, including for polymicrobial samples (reported: ~8 hours blood, ~6 hours urine).
Differential chromogenic media assay for Candida species (96-well)
96‑well plate format differential media for visual colorimetric discrimination of Candida species (including Candida auris) after incubation (36–54 hours), with optional automated plate reader readout.
Expertise Areas
- Clinical microbiology diagnostics
- Rapid infectious disease testing
- Antimicrobial susceptibility testing (AST)
- In vitro respiratory models (ALI) and aerosol exposure
Key Technologies
- Air-liquid interface (ALI) airway epithelial cell models
- 96‑well plate-based chromogenic assays
- Plate reader automation and data interfacing
- Ames, MTS, micronucleus and Comet assays
Key People
Investors
Seed Round - Spectral Platforms
$675,000 funded.
Announced on 2015-07-10.
Seed Round - Spectral Platforms
$675,000 funded.
Announced on 2015-07-10.
News & Updates
Spectral Platforms was one of 10 Step 1 winners in the AMR (Antimicrobial Resistance) Challenge, recognizing innovation in rapid diagnostics.
Patent issued for albumin-based non-covalent complexes and methods of use, foundational to the company's diagnostic technology.
USPTO issued a notice of allowance for a key patent application, strengthening the company's IP portfolio.
Explores surprising scientific findings from jellyfish and their medical implications.
Discusses approaches and findings related to minimizing side effects of medicines.
Examines why the flu virus does not spread as expected and the implications for public health.
Spectral Platforms was one of 10 Step 1 winners in the AMR (Antimicrobial Resistance) Challenge, recognizing innovation in rapid diagnostics.
Patent issued for albumin-based non-covalent complexes and methods of use, foundational to the company's diagnostic technology.
USPTO issued a notice of allowance for a key patent application, strengthening the company's IP portfolio.
Explores surprising scientific findings from jellyfish and their medical implications.
Discusses approaches and findings related to minimizing side effects of medicines.
Examines why the flu virus does not spread as expected and the implications for public health.